Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

4 clinical studies listed.

Filters:

Plasma Cell Disorders

Tundra lists 4 Plasma Cell Disorders clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT06252948

Gut Microbiome Studies in Patients With POEMS Syndrome and Other Plasma Cell Disorders

A Study to Evaluate Gut Microbiome with POEMS Syndrome and Other Plasma Cell Disorders

Gender: All

Ages: 18 Years - Any

Updated: 2026-02-23

1 state

Plasma Cell Disorders
RECRUITING

NCT06644625

CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study

The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and improve long term outcomes.

Gender: All

Ages: 30 Years - Any

Updated: 2026-01-20

1 state

Multiple Myeloma
Multiple Myeloma Progression
Monoclonal Gammopathy of Undetermined Significance (MGUS)
+2
RECRUITING

NCT07115667

Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration

This is a prospective, single-arm, single-center clinical trial designed to evaluate the safety and efficacy of radiation combined with a BCMA/CD3 bispecific antibody (CM336) in patients with solitary bone plasmacytoma (SBP) with mild bone marrow infiltration.

Gender: All

Ages: 18 Years - 78 Years

Updated: 2025-09-08

Solitary Bone Plasmacytoma
Plasmacytoma of Bone
Plasma Cell Disorders
NOT YET RECRUITING

NCT06286215

Registry of Patients With Plasma Cell Disorders

The goal of this observational study is to register patients with plasma cell disorders. The main questions it aims to answer are: * The incidence of plasma cell disorders both before and after malignancy * Time to progression of monoclonal gammopathy of undetermined significant (MGUS) or smoldering multiple myeloma (SMM) to light chain amyloidosis or multiple myeloma (MM) * Progression free survival (PFS) * overall survival * factors influencing overall survival, progression-free survival, and time to progression * Symptoms and signs of the disease during the diagnosis and relapse phases, including the causes of mortality in plasma cell disorder patients. * genetic characteristics of plasma cell disorder * cost-effectiveness of treatment in Thailand Participants will be collected the data of baseline diagnosis, treatment, treatment results of all admission and follow-up visits from hospital medical record.

Gender: All

Ages: 18 Years - Any

Updated: 2024-02-29

Plasma Cell Disorders